SCHEMBL25546359

SCHEMBL25546359

CC(C)Cc1sc(Cl)nc1-c1cccc(OCc2ccccc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 2/20 0.44
IGF1R P08069 1/20 0.43
BACE1 P56817 1/20 0.42
MAOB P27338 2/20 0.42
F9 P00740 1/20 0.41
F10 P00742 1/20 0.41
NR1H2 P55055 1/20 0.41
CYP3A4 P08684 2/20 0.40
EGFR P00533 1/20 0.40
RAF1 P04049 1/20 0.40
ARAF P10398 1/20 0.40
BRAF P15056 1/20 0.40
KDR P35968 1/20 0.40
MAP2K2 P36507 1/20 0.40
FLT3 P36888 1/20 0.40
KCNH2 Q12809 1/20 0.40
ERBB4 Q15303 1/20 0.40
HPGD P15428 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25546032 0.86 KMT2A (0.47) HPGDKMT2AALDH1A1TSHRMAPK1
SCHEMBL25546356 0.84 KDM4E (0.46) HPGDKMT2AALDH1A1LMNATSHR
SCHEMBL25545933 0.83 TDP1 (0.44) PDE4BHPGDALDH1A1LMNASMN1; SMN2
SCHEMBL25546513 0.83 SMN1; SMN2 (0.47) KMT2ASMN1; SMN2MEN1FBP1
SCHEMBL25546364 0.83 FBP1 (0.45) IGF1RHPGDKMT2ASMN1; SMN2FBP1
SCHEMBL25546355 0.83 FBP1 (0.42) KMT2ASMN1; SMN2FBP1
SCHEMBL25546361 0.82 FBP1 (0.43) PDE4BKMT2ANPSR1LMNATSHR
SCHEMBL25546349 0.82 FBP1 (0.39) BACE1KCNH2KMT2AFBP1
SCHEMBL25546334 0.80 FBP1 (0.44) ALDH1A1FBP1
SCHEMBL29224039 0.79 FBP1 (0.40) PDE4BLMNASMN1; SMN2FBP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 PDE4B 1760/4885IGF1R 3089/4885BACE1 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.